Plant architecture is a major consideration during the commercial production of chrysanthemum (Dendranthema grandiflora Tzvelev). We have addressed this problem through a biotechnological approach: genetic engineering of chrysanthemum cv. Iridon plants that ectopically expressed a tobacco phytochrome B1 gene under the control of the CaMV 35S promoter. The transgenic plants were shorter, greener in leaves, and had larger branch angles than wild-type (WT) plants. Transgenic plants also phenocopied WT plants grown under light condition depleted of far-red wavelengths. Furthermore, the reduction of growth by the expressed PHY-B1 transgene did not directly involve gibberellins. The commercial application of this biotechnology could provide an economic alternative to the use of chemical growth regulators, and thus reduce the production cost.